Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19…
UNIONDALE, N.Y., June 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and…